NASDAQ · HYFT
Healthcare · Biotechnology
$1.10
Down-$0.06 (-5.45%)
Updated Nov 4, 2026, 9:03 PM
SID Score
3.2/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · HYFT
1M range · 0 trading sessions · Daily adjusted prices
HYFT does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
The latest Smart Investors Daily articles mentioning HYFT.
Company
Market Activity
Research & News
HYFT research
Company profile and research snapshot.
MindWalk Holdings Corp is a Bio-Native AI company transforming drug discovery and development. Powered by patented HYFT technology and the LensAI platform, MindWalk unifies sequence, structure, function, and literature into a single computational language and closes the loop with an integrated, full-stack wet lab. The platform supports rapid epitope mapping, de novo molecular design, in silico vaccine exploration, and population-scale biologics analytics that help turn insights into validated candidates at speed.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| May 19, 2026 | HC Wainwright & Co. | Buy | — |
| Apr 16, 2026 | Jones Trading | Buy | — |
No generated briefing is available yet.
Yahoo · Oct 22, 2026
AUSTIN, Texas, October 22, 2026--MindWalk Holdings Corp. ("MindWalk") (NASDAQ: HYFT), a Bio-Native AI company, today announced that Thomas Lynch, PhD, has departed the company and ceased to serve as Chief Business Officer, effective October 16, 2026.
Yahoo · Oct 21, 2026
AUSTIN, Texas, October 21, 2026--MindWalk Holdings Corp. ("MindWalk") (NASDAQ: HYFT), a Bio-Native AI company, today published a white paper showing that its LensAI™ immunogenicity screening ran across an entire public antibody database of 890,634 sequences in 4 hours and 41 minutes on Amazon EC2 Hpc8a instances powered by 5th Gen AMD EPYC™ processors, delivering up to 43% lower cost per sequence than a comparable Intel configuration running identical code.
Yahoo · Oct 14, 2026
BOSTON, October 14, 2026--MindWalk Holdings Corp. (NASDAQ: HYFT) ("MindWalk" or the "Company"), a Bio-Native AI company, today announced three senior appointments that strengthen its Boston-based development leadership as the Company’s pipeline advances toward preclinical efficacy studies. Zachary Maben, PhD, joins as Director, Antigen Discovery & Protein Engineering, from Arbor Biotechnologies and previously Pfizer. Joanne Lim, PhD, joins as Director, Preclinical Development, from Orum Therapeu
Yahoo · Oct 6, 2026
AUSTIN, Texas, October 06, 2026--MindWalk Holdings Corp. ("MindWalk") (NASDAQ: HYFT), a Bio-Native AI company, today outlined why the ontology layer now being built across enterprise AI does not reach biological function, and why life sciences requires a biological context layer of its own. ReefIQ™, MindWalk's biological context layer for life sciences, supplies what a horizontal ontology cannot: a governed, model-agnostic representation of what biology does, available from the first day of a de
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning HYFT.
